CVS Health Corporation (NYSE:CVS – Get Free Report) shares passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $88.94 and traded as high as $89.08. CVS Health shares last traded at $89.0330, with a volume of 15,100,658 shares trading hands.
Latest CVS Health News
Here’s some of the latest news about CVS:
- Positive Sentiment: Wells Fargo cut its price target to $112 from $123 but kept an “overweight” rating, signaling continued optimism despite a more cautious valuation. Article: Wells Fargo lowers CVS price target
- Neutral Sentiment: CVS’s planned 2028 split could sharpen strategic focus, improve capital allocation and help investors value its businesses separately. The potential upside depends on execution and whether the separation delivers meaningful benefits. Article: Can CVS Health’s 2028 Split Unlock Value Despite Execution Risks?
- Negative Sentiment: Criticism of the breakup highlights that separation may not resolve concerns about the businesses CVS plans to retain together. Operational complexity, costs and ongoing pressure on its pharmacy-benefit-management business and membership remain risks. Article: CVS Health CEO doesn’t expect end to criticism with split plans
Analysts Set New Price Targets
A number of research analysts recently weighed in on CVS shares. Wells Fargo & Company decreased their target price on CVS Health from $123.00 to $112.00 and set an “overweight” rating on the stock in a report on Thursday. Barclays cut their price target on CVS Health from $108.00 to $107.00 and set an “overweight” rating for the company in a report on Thursday, November 5th. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a report on Thursday, August 6th. Wall Street Zen lowered shares of CVS Health from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 19th. Finally, Evercore restated an “outperform” rating on shares of CVS Health in a research note on Wednesday, November 4th. Twenty-three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.79.
Check Out Our Latest Report on CVS
CVS Health Stock Up 0.2%
The firm has a 50-day moving average price of $89.81 and a 200 day moving average price of $89.00. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.85 and a quick ratio of 0.66. The company has a market cap of $114.76 billion, a price-to-earnings ratio of 10.44, a P/E/G ratio of 0.77 and a beta of 0.58.
CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.65 by $0.44. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.60 earnings per share. Sell-side analysts predict that CVS Health Corporation will post 8.26 EPS for the current year.
CVS Health Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd were issued a dividend of $0.6650 per share. The ex-dividend date of this dividend was Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. CVS Health’s dividend payout ratio (DPR) is currently 30.97%.
Insider Buying and Selling at CVS Health
In other CVS Health news, EVP Prem Shah bought 23,855 shares of CVS Health stock in a transaction dated Friday, November 6th. The stock was bought at an average price of $83.89 per share, with a total value of $2,001,195.95. Following the completion of the transaction, the executive vice president owned 88,516 shares in the company, valued at $7,425,607.24. The trade was a 36.89% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.
Hedge Funds Weigh In On CVS Health
Hedge funds have recently bought and sold shares of the business. Kilter Group LLC acquired a new position in shares of CVS Health during the 2nd quarter worth approximately $27,000. J.Safra Asset Management Corp bought a new position in shares of CVS Health during the second quarter worth approximately $30,000. Beaird Harris Wealth Management LLC raised its position in shares of CVS Health by 201.0% in the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 195 shares in the last quarter. Timbuktu Capital Management LLC acquired a new stake in shares of CVS Health in the second quarter valued at approximately $31,000. Finally, Dunhill Financial LLC acquired a new stake in shares of CVS Health in the second quarter valued at approximately $32,000. 80.66% of the stock is owned by institutional investors.
About CVS Health
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Further Reading
- Five stocks we like better than CVS Health
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
